Smith et al. evaluated preoperative CA

19-9 serum levels in 109 pancreatic cancer patients who underwent a pancreatoduodenectomy and noted a median survival of only 10.4 months in patients with a preoperative CA19-9 level >150 U/mL (n=64), compared to a median survival of 22.1 months in patients with a CA19-9 serum level ≤150 U/mL (n=45, P=0.012) (45). Table 3 lists additional studies which have used various cut-off levels for pre-operative CA 19-9 serum levels in an effort to predict survival among Inhibitors,research,lifescience,medical pancreatic cancer patients (22,24,26,30,31,38-49). These studies support the conclusion that a normal (<37 U/mL) or low preoperative CA 19-9 serum level (<100 U/mL) correlates with early pancreatic cancer stage and independently predicts improved overall survival, whereas an elevated CA 19-9 serum levels (>100 U/mL) is associated with a poor NVP-BGJ398 in vitro prognosis (38-49). Table 4 Pre-operative CA 19-9 serum levels in pancreatic cancer patients correlate not only Inhibitors,research,lifescience,medical with stage of disease, but also independently predict overall survival. An undetectable level or a CA 19-9

serum level of <37 U/mL is associated with a median ... Several authors have reported on the prognostic significance of the post-operative CA Inhibitors,research,lifescience,medical 19-9 serum levels in predicting survival. Ferrone et al. analyzed 111 pancreatic cancer patients in whom pre- and post-operative CA 19-9 serum levels were measured. Post-operative CA 19-9 serum levels of <37 U/mL were associated with Inhibitors,research,lifescience,medical a mean survival of 2.4 years, a level of <200 U/mL had a mean survival Inhibitors,research,lifescience,medical of 2.3 years,

whereas a post-operative CA 19-9 serum levels of <1000 U/mL and >2000 U/mL had a mean survival of 9 and 5 months respectively. Overall a low postoperative serum CA 19-9 level (<200 U/mL) was an independent predictor of survival (24). Kondo et al. studied pre- and postoperative CA19-9 serum levels in 109 surgically treated pancreatic cancer patients and identified that both a normal postoperative CA 19-9 serum level (37 U/mL) [Hazard Ratio (HR) 1.64, P=0.004], and the addition of adjuvant chemotherapy were independent predictors of prognosis (26). More specifically these authors identified that a post-operative CA 19-9 serum Resveratrol level measured at 2-5 weeks could independently predict a prolonged 3- year survival rate. Post-operative CA 19-9 serum levels of <37 U/mL, <200 U/mL and >500 U/mL were associated with a 49%, 38%, and 0% 3-year survival rates respectively. Elevated CA 19-9 (>35 U/mL) in the immediate post-operative period was also associated with an R1 resection and lymph node metastases (P=0.041) (26). Montgomery et al.